Aprea Therapeutics (Nasdaq: APRE) Advances Cancer Pipeline as Maxim Group Sets $10 Price TargetAprea Therapeutics (Nasdaq: APRE) a clinical-stage oncology company developing next-generation cancer therapies — reported strong third-quarter progress as its lead drug programs continue to show encouraging clinical activity in multiple genetically driven cancers. The company’s precision-oncology approach targets defects in DNA damage repair (DDR) pathways including p53, WEE1, and ATR, which are common drivers of aggressive solid tumors and blood cancers such as colorectal, endometrial, ovarian, pancreatic, lung cancers, MDS, and AML .
Macau-Based Epsium Enterprise Limited Celebrates Nasdaq Listing with Closing Bell CeremonyEPSIUM ENTERPRISE LIMITED (Nasdaq: EPSM) (“EPSIUM” or the “Company”), a Macau-based importer and wholesaler primarily of high-end alcoholic beverages, today announced that it celebrated its recent Nasdaq listing by ringing the Nasdaq Closing Bell on Thursday, May 29, 2025.
D. Boral Capital Acted as Sole Bookrunner to EPSIUM ENTERPRISE LIMITED (Nasdaq: EPSM) in connection with its $5.0 Million Initial Public OfferingNEW YORK CITY, NY / ACCESS Newswire / March 31, 2025 / On March. 27, 2025, EPSIUM ENTERPRISE LIMITED (Nasdaq:EPSM) (the "Company" or "EPSIUM"), a company engaged in importing and wholesaling primarily alcoholic beverages in Macau, announced the closing of its initial public offering (the "Offering") of 1,250,000 ordinary shares at a public offering price of US$4.00 per ordinary share. The ordinary shares began trading on the Nasdaq Capital Market on March 26, 2025 under the ticker symbol "EPSM."
